Sorrento Therape
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, includi… Read more
Market Cap & Net Worth: Sorrento Therape (SRNE)
Sorrento Therape (OTCQB:SRNE) has a market capitalization of $551.28K ($551.28K) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #37358 globally and #12162 in its home market, demonstrating a 42.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sorrento Therape's stock price $0.00 by its total outstanding shares 551281154 (551.28 Million).
Sorrento Therape Market Cap History: 2015 to 2025
Sorrento Therape's market capitalization history from 2015 to 2025. Data shows change from $4.80 Billion to $551.28K (-61.64% CAGR).
Sorrento Therape Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sorrento Therape's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.77x
Sorrento Therape's market cap is 7.77 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.80 Billion | $4.59 Million | -$45.81 Million | 1046.11x | N/A |
| 2016 | $2.70 Billion | $8.15 Million | -$60.92 Million | 331.36x | N/A |
| 2017 | $2.09 Billion | $151.86 Million | $9.13 Million | 13.80x | 229.40x |
| 2018 | $1.32 Billion | $21.19 Million | -$203.54 Million | 62.43x | N/A |
| 2019 | $1.86 Billion | $31.43 Million | -$359.10 Million | 59.28x | N/A |
| 2020 | $3.76 Billion | $39.99 Million | -$308.57 Million | 94.10x | N/A |
| 2021 | $2.56 Billion | $52.90 Million | -$429.01 Million | 48.45x | N/A |
| 2022 | $488.44 Million | $62.84 Million | -$559.33 Million | 7.77x | N/A |
Competitor Companies of SRNE by Market Capitalization
Companies near Sorrento Therape in the global market cap rankings as of March 18, 2026.
Key companies related to Sorrento Therape by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Sorrento Therape Historical Marketcap From 2015 to 2025
Between 2015 and today, Sorrento Therape's market cap moved from $4.80 Billion to $ 551.28K, with a yearly change of -61.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $551.28K | -33.33% |
| 2024 | $826.92K | -98.79% |
| 2023 | $68.08 Million | -86.06% |
| 2022 | $488.44 Million | -80.95% |
| 2021 | $2.56 Billion | -31.87% |
| 2020 | $3.76 Billion | +101.92% |
| 2019 | $1.86 Billion | +40.83% |
| 2018 | $1.32 Billion | -36.84% |
| 2017 | $2.09 Billion | -22.45% |
| 2016 | $2.70 Billion | -43.74% |
| 2015 | $4.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Sorrento Therape was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $551.28K USD |
| MoneyControl | $551.28K USD |
| MarketWatch | $551.28K USD |
| marketcap.company | $551.28K USD |
| Reuters | $551.28K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.